
ARE Stock Forecast & Price Target
ARE Analyst Ratings
Bulls say
Alexandria Real Estate Equities Inc. is positioned for growth due to its strong market presence in key urban life science hubs, which is expected to benefit from increased tenant demand and the projected upturn in biotech valuations that could enhance capital formation and the need for lab space. The potential for recovery in private sector demand, coupled with substantial government budget commitments, is likely to bolster the demand for purpose-built spaces in the life science sector. Additionally, a robust backlog in construction and strategic opportunities in the concessions segment further support a positive outlook for the company's revenue growth and overall financial performance.
Bears say
Alexandria Real Estate Equities Inc faces significant challenges that contribute to a negative outlook for its stock. The company is experiencing a downturn due to lower operating results, higher anticipated occupancy erosion, and delays in the lease-up of new developments, compounded by an oversupply of life science properties exacerbated by weak demand from tenants. Furthermore, ongoing factors such as slowed capital formation in the life science sector and the impending impact of government actions on drug approvals contribute to an unfavorable forecast for future earnings growth and occupancy rates.
This aggregate rating is based on analysts' research of Alexandria Real Estate Equities and is not a guaranteed prediction by Public.com or investment advice.
ARE Analyst Forecast & Price Prediction
Start investing in ARE
Order type
Buy in
Order amount
Est. shares
0 shares